RXi Pharmaceuticals Corporation (NASDAQ:RXII) is set to announce its earnings results after the market closes on Wednesday, November 8th.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). During the same quarter last year, the firm posted ($0.34) earnings per share. On average, analysts expect RXi Pharmaceuticals Corporation to post $-0.74 EPS for the current fiscal year and $-0.57 EPS for the next fiscal year.

RXi Pharmaceuticals Corporation (NASDAQ RXII) opened at 0.545 on Wednesday. RXi Pharmaceuticals Corporation has a one year low of $0.32 and a one year high of $2.93. The company has a 50 day moving average of $0.53 and a 200-day moving average of $0.58. The firm’s market cap is $12.67 million.

In related news, insider Alexey Eliseev sold 176,800 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total value of $95,472.00. Following the transaction, the insider now owns 1,100,931 shares in the company, valued at $594,502.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “RXi Pharmaceuticals Corporation (RXII) Scheduled to Post Quarterly Earnings on Wednesday” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/01/rxi-pharmaceuticals-corporation-rxii-scheduled-to-post-quarterly-earnings-on-wednesday.html.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.